

AD _____

AWARD NUMBER DAMD17-97-1-7159

TITLE: The Mechanism by Which Agonist and Antagonist Occupied
Progesterone Receptors Regulate Target Genes

PRINCIPAL INVESTIGATOR: Maria Cristina Keightley, Ph.D.

CONTRACTING ORGANIZATION: Baylor College of Medicine
Houston, Texas 77030-3498

REPORT DATE: June 1998

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

19980813 064

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 1

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE June 1998	3. REPORT TYPE AND DATES COVERED Annual (15 May 97 - 14 May 98)	
4. TITLE AND SUBTITLE The Mechanism by Which Agonist and Antagonist Occupied Progesterone Receptors Regulate Target Genes			5. FUNDING NUMBERS DAMD17-97-1-7159	
6. AUTHOR(S) Keightley, Maria Cristina, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine Houston, Texas 77030-3498			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) Progesterone has been shown to play a role in the proliferation of breast cancer cells, thus the development and use of anti-progestins, such as RU 486, may serve as a useful treatment by blocking the stimulatory effects of progesterone. Progesterone exerts its biological effects through its receptor (hPR) which belongs to a superfamily of transcription factors. All steroid receptors have been shown to be phosphoproteins and agents which regulate phosphorylation have been demonstrated to affect progesterone receptor action. It is therefore important to study the mechanism by which phosphorylation impinges on progesterone receptor function, and in particular, how it enables 8-Br-cAMP to switch the antagonist RU 486 into an agonist. In this study thus far, three hPR-B specific phosphorylation sites have been mutated to non-phosphorylatable residues and the activities and protein levels of these mutant PR examined.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 37	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

✓ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

✓ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

✓ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

 6/10/98
PI - Signature Date

Table of Contents

	Page
Introduction	2
Body	6
Methods	6
Results and Discussion	8
Conclusions	14
Figures	18
References	32

Introduction

Progesterone plays a central role in the regulation of many reproductive processes, particularly in the development of the alveolar system in mammary glands and in the establishment and maintenance of pregnancy (1-3). In addition, high doses of progesterone and its stable synthetic derivatives have been used as an anti-proliferative cancer treatment (4). Progesterone has also been shown to play a role in the proliferation of breast cancer cells (5) and, as such, the development and use of anti-progestins may serve as a useful treatment by blocking the stimulatory effects of progesterone.

Progesterone exerts its biological effects through its receptor which belongs to a superfamily of steroid/thyroid/retinoid receptors which act as transcription factors (6,7). These receptors are characterized by a highly conserved DNA-binding domain which is flanked by a poorly conserved N-terminal domain and a C-terminal ligand-binding domain. The human progesterone receptor exists as two naturally occurring A and B forms which are derived from separate messages (8,9). The two isoforms differ in size, with hPR-A being ~94,000 Da in size whereas the larger hPR-B is ~120,000 Da in size. They share the same coding sequence except that hPR-B has an additional 164 amino-acids at its N-terminal which account for its increased size. There is increasing evidence that these two isoforms are functionally distinct (10,11). Although both can be transcriptionally active, depending on the promoter context (10), hPR-B appears to be a stronger activator of gene transcription in response to hormone. hPR-A has also been shown to be a promiscuous repressor capable of repressing not only the activity of hPR-B, but also that of the estrogen, androgen, mineralocorticoid and glucocorticoid receptors (10,11).

The hormone dependent pathway of receptor activation involves binding of ligand to the receptor and dissociation of heat-shock protein complex, dimerization of the receptor and translocation to the nucleus. The receptor dimer then binds to its cognate response element in the promoter region of steroid responsive genes, and through recruitment of coactivator proteins and displacement of repressor proteins, enables transcriptional regulation of the expression of target genes.

Phosphorylation is a key regulator for transcription factors, kinases and cell cycle proteins, providing a mechanism whereby signals from other cellular pathways can be received and integrated resulting in a tightly coordinated response to stimuli. Generally, phosphorylation of transcription factors serves to modulate activity rather than acting as an on/off switch. This can occur as a result of enhancing/blocking DNA-binding activity (CREB and c-jun) (12,13), altering interaction with inhibitors (eg NFkB and c-jun) (14,15) and affecting interactions with other proteins (CREB) which leads to a subsequent decrease/increase in target gene transcription (16). There are frequently multiple phosphorylation sites on transcription factors and it is the phosphorylation of specific combinations of these sites that determines the overall effect on function.

All steroid receptors have been identified as phosphoproteins, with most showing increased phosphorylation in response to hormone (17-19). Although serine/threonine residues constitute the majority of phosphorylation sites, phosphotyrosine has also been identified in the human estrogen receptor (20,21) and retinoic acid receptor β (22). Pioneering studies in the steroid

receptor phosphorylation field identified four ser-pro motifs which are phosphorylated in the chick PR, two of which are constitutively phosphorylated and two of which are highly hormone inducible (17,23). More recently, phosphorylation of the human PR in T47D cells has been shown to increase in response to hormone (24). Subsequently, seven *in vivo* phosphorylation sites have been identified for the human PR, Ser⁸¹, Ser¹⁰², Ser¹⁶², Ser¹⁹⁰, Ser²⁹⁴, Ser³⁴⁵ and Ser⁴⁰⁰, with Ser¹⁰², Ser²⁹⁴ and Ser³⁴⁵ being hormone inducible and three of these sites being specific to hPR-B: Ser⁸¹, Ser¹⁰² and Ser¹⁶² (25,26). We expect the remaining one or two sites to be confirmed within the next year. Thus far in our functional analysis we have found that mutation of Ser⁸¹ to a non-phosphorylatable alanine results in a decrease in transactivation compared to wild-type hPR-B.

There is increasing evidence to suggest that like estrogen, progesterone may induce strong proliferation of breast epithelium (5). Indeed, in mice lacking PR, terminal end bud proliferation and differentiation is severely compromised (27). RU 486 has been shown *in vivo* to act mainly as a classical progesterone antagonist and such antagonists have been shown to inhibit the development of mammary gland buds (28), suggesting a clinical role for RU 486 in the treatment of breast cancer. In addition to being activated in a hormone-dependent manner, the chick PR can also activate target genes in response to kinase modulators such as 8-Br-cAMP and okadaic acid, a phenomenon described as ligand-independent activation of the receptor (29). Although the human PR is unable to undergo ligand-independent activation as such, response to hormone is significantly augmented in the presence of these agents (24). Potentially more important is the observation that in the presence of 8-Br-cAMP, RU 486 switches from an antagonist to an agonist (30). The ramifications of this are immediately apparent, especially since deregulation of

cancer cell growth can be due to over-expression of oncogenes coding for kinases which subsequently alter the phosphorylation status of proteins inside the cell. It is clearly necessary to understand the mechanism by which this switch can occur.

My hypothesis is that the B-specific region of hPR confers unique functions to the hPR-B isoform via at least 3 unique phosphorylation sites and interaction with another protein(s), resulting in the separate transactivation function (AF3) assigned to this region, the increased transcriptional activity of hPR-B compared to hPR-A in response to hormone, and the ability of hPR-B to mediate a functional antagonist/agonist switch for RU 486.

The aim of this project is to functionally characterize the hPR-B-specific phosphorylation sites Ser⁸¹, Ser¹⁰², and Ser¹⁶², with a view to examining the role of phosphorylation in receptor-mediated transactivation and interaction with other proteins, and the antagonist/agonist RU 486 switch.

BODY

Methods:

Cell culture and transient transfection

Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies Gibco BRL) containing 10% fetal bovine serum (FBS). Cells were plated in DMEM containing 5% charcoal stripped serum at a confluency of 50-60%. On the day of transfection the medium was replaced with fresh DMEM (no serum). Adenovirus mediated transfection was carried out according to the protocol in Allgood et al (31). Briefly, the desired amount of receptor and reporter DNA was mixed with adenovirus at a multiplicity of infection of 250:1. Following incubation at room temperature (RT) for 30 min, polylysine was added and a further incubation at RT for 30 min was carried out. The cocktail was then added to each well and incubated at 37°C/5%CO₂ for 2 hours (h). An equal volume of DMEM containing 10% charcoal stripped serum was then added to each well to bring the final serum concentration to 5%. 24h post-transfection, cells were treated as indicated and the following day the cells were harvested in 0.4M sodium chloride/Tris/EDTA/monothioglycerol and after undergoing three cycles of freeze/thawing were collected by centrifugation and the protein concentration determined by Bradford assay (Biorad). Cell extracts containing equivalent amounts of protein were then assayed for chloramphenicol acetyl transferase activity using a liquid assay.

For the studies with the Schule series of reporters, cells were transfected with Lipofectamine according to the manufacturer's directions (Life Technologies Gibco BRL) and assayed as described above.

Whole cell hormone binding assay

Cells were transfected using the adenovirus method. 48h post-transfection medium was removed from the cells and replaced with DMEM containing decreasing concentrations of [3 H]R5020 (Amersham) (1-0.05nM) and incubated for 2h at 37°C/5%CO₂. The medium was then aspirated and the cells washed three times with ice cold PBS. 1ml ethanol was added and left at RT for 15min. 800ul of each sample was added to 8ml of scintillation fluid and released [3 H]R5020 counted in a liquid scintillation counter (Beckman). The amount of bound radioactivity was determined by subtracting mock transfected wells from PR transfected wells. The amount of free radioactivity was determined by subtracting the amount of bound radioactivity from the original amount of radioactivity added as determined by counting the radioactive medium before addition to the wells.

Construction of mutants

Mutants were constructed using the Clontech transformer mutagenesis kit. The selection oligonucleotide is: TTCACACCGCATATGGTGCACTCT. The mutant oligonucleotides are as follows: GCAGTCGCTGGCTGACGTGGAGG (for Ala⁸¹); GACCAGCAGTCGCTGGCGG ACGTGGAGGGCGCA (for Glu⁸¹); GGCAGCAGTTCTGCTCCCCCAGAAAAGG (for Ala¹⁰²); and ACCCAGCGGGTGTTGGCCCCGCTCATGAGCCGG (Ala¹⁶²).

Western analysis

Equivalent amounts of protein are electrophoresed on an SDS-polyacrylamide gel and transferred to a nitrocellulose membrane (BA85; Schleicher and Schuell). The #1294 anti-PR antibody was used according to Dean Edwards' protocol. A secondary rabbit anti-mouse antibody (Zymed)

followed by a horseradish peroxidase conjugated donkey anti-rabbit antibody (Amersham) were used prior to detection of the signal using enhanced chemiluminescence (Amersham).

Results and Discussion:

Mutation of Ser⁸¹ to alanine results in a decrease in transactivation compared to wild type PR

Cells were transfected with wild type and mutant PR, and CAT activity assayed. Fig. 1 shows that compared to wild type hPR-B, the Ala⁸¹ mutant has decreased transcriptional activity in CV-1 cells using a simple GRE₂E1b-CAT promoter. A number of cell lines were subsequently examined to determine if different cellular contexts would affect transcriptional outcome. Fig. 2 shows that in Hela cells, transcriptional activity of the Ala⁸¹ mutant is still lower than that of wild type hPR-B. Cell lines that were tested with similar results include COS and MCF-10. Since the decrease in activation could be due to a decrease in hormone binding activity, or a decrease in the overall amount of protein expressed in the cell, rather than a decrease in the intrinsic activation capacity per molecule of receptor, it was necessary to examine these possibilities.

Mutation of Ser⁸¹ to Ala⁸¹ does not cause phosphorylation at alternate sites.

In order to confirm that mutating the Ser⁸¹ phosphorylation site did not result in ectopic phosphorylation elsewhere on the receptor and that this mutation did indeed abolish phosphorylation at this site, cells were labeled *in vivo* with [³²P]-orthophosphate and phosphopeptide maps obtained show the absence of phosphopeptide containing Ser⁸¹, and the

absence of any alternate phosphopeptides compared to wild type receptor. This work was carried out in our collaborator, Dean Edwards' laboratory.

Mutation of Ser⁸¹ to Glu⁸¹ does not radically alter receptor phenotype.

The Glu⁸¹ mutant was constructed as described in methods and analyzed alongside the wild type hPR-B and Ala⁸¹ mutant. As is seen in Fig. 3, mutation of Ser⁸¹ to Glu does not drastically alter PR activity and brings it a little closer to that of wild type receptor as might be expected if the constant negative charge provided by the glutamic acid residue is able to mimic the negative charge provided by the phosphate group.

Wild type hPR-B and Ala⁸¹ mutant have the same hormone binding affinity.

COS cells were transfected with either wild type hPR-B or Ala⁸¹ mutant and whole cell binding assays performed with [³H]-R5020 to determine hormone binding affinity by Scatchard analysis. Experiments performed 5 times, (Fig. 4) showed that both hPR-B and the Ala⁸¹ mutant bind R5020 with very similar affinity, K_d = 0.5nM. Of note is the shifting of the Ala⁸¹ mutant slope to the left indicating a decrease in the number of hormone binding sites, possibly reflecting lower expression of the Ala⁸¹ mutant protein.

Western analysis of wild type hPR-B and Ala⁸¹ mutant PR

Given the results of the hormone binding assay which showed a shift to the left for the Ala⁸¹ mutant PR indicating a decrease in the number of hormone binding sites, and that the mutant phenotype shows a decrease in transactivation, I wished to determine the expression levels of wild type hPR-B and the Ala⁸¹ mutant in cells transfected with close to physiological amounts of receptor. These studies proved technically challenging since the antibodies for PR are notoriously low affinity. When I began these studies, I could only detect PR protein in cells transfected with saturating amounts of receptor DNA, and at these levels of DNA there were no apparent differences in receptor expression level. However, it was important to me to be able to analyze receptor protein when the DNA in the transfection was in the same linear range used for the CAT assays where I was able to see a difference in transactivation between wild type hPR-B and the mutant; preferably, out of the same cell extract.

Recently, I have been able to do this using a new antibody developed in our collaborator, Dean Edwards', laboratory. Fig. 5 shows that in HeLa cells where transcriptional activity of Ala⁸¹ mutant is lower than that of wild type hPR-B, the protein levels appear to mirror the transcriptional activity suggesting that this drop in activity may be due to a decrease in protein expression or a more rapid turnover/decreased stability of the Ala⁸¹ mutant PR. These results are preliminary, however, and will be repeated in order to establish if this is indeed true. Other ways of analyzing the same question include ³⁵S-methionine labeling of cells to steady-state and determining turnover for wild type versus mutant PR. In addition, examining protein levels after

blocking protein synthesis with cycloheximide will address the same question. These studies are in progress.

Analysis of hPR-B and Ala81 transcriptional activity on a complex promoter.

Recently, it is becoming apparent that receptor-mediated transcription of target genes involves recruitment of proteins such as coactivators and corepressors that act as a bridge between the receptor and the transcriptional machinery of the cell. Phosphorylation of steroid receptors may then affect the interactions with these and other possible transcription cofactors that might be needed for target gene regulation. Such an effect is more likely to be detected on complex promoters which contain binding sites for other transcription factors rather than the simple response elements contained within GRE₂E1bCAT. The transcriptional activity of hPR-B wild type versus the Ala⁸¹ mutant PR was therefore examined using a mouse mammary tumor virus promoter linked to a CAT reporter (MMTV-CAT). Fig. 6 shows that in both HeLa and CV-1 cells the Ala⁸¹ mutant PR still appears to show reduced activity although it is somewhat less than the reduction observed with the GRE₂E1bCAT. Although no dramatic change in the phenotype of the phosphorylation site mutant PR was observed in this case, it remains important to investigate a variety of complex promoters which may be able to define the role of specific phosphorylation sites in interacting with particular transcription factors.

Analysis of Ala¹⁰² mutant PR transcriptional activity

The Ala¹⁰² mutant was constructed as described in Methods and analyzed by transfection and CAT assay. Using a GRE₂E1bCAT reporter in HeLa cells, the activity of the Ala¹⁰² mutant does not appear to be compromised compared to wild type hPR-B as seen in Fig. 7. Since it was necessary to determine protein expression levels before any conclusions could be drawn, Western analysis was performed on the samples.

Western analysis of Ala¹⁰² mutant.

When analyzing protein levels for the Ala¹⁰² mutant it became apparent that mutating Ser¹⁰² to alanine eliminated the slower migrating upper band observed with wild type hPR-B using Western analysis (Fig. 8). This suggests a distinct conformational change in the receptor in the absence of phosphorylated Ser¹⁰². The levels of receptor protein, however, again seem to reflect that amount of transactivation relative to wild type hPR-B suggesting that under these conditions phosphorylation of this site may not affect transcriptional activity.

Hormone binding analysis of the Ala¹⁰² mutant

In order to confirm that the hormone binding affinity of the Ala¹⁰² mutant was not altered, hormone binding assays were carried out. Fig. 9 shows a whole cell hormone binding assay for Ala¹⁰² and wild type hPR-B. Scatchard analysis shows the affinities of both wild type and

mutant PR for R5020 are virtually indistinguishable with a K_d of 0.16 nM for wild type hPR-B and 0.20 nM for the Ala¹⁰² mutant.

Analysis of the Ala¹⁶² mutant

The Ala¹⁶² mutant was constructed as described in Methods. Cells were transfected with wild type hPR-B and Ala¹⁶² mutant to examine transcriptional activity. As is shown in Fig. 10, the Ala¹⁶² mutant PR does not show a dramatic difference in transcriptional activity as compared with wild type hPR-B.

Western and hormone binding analysis of the Ala¹⁶² mutant.

Western analysis of the Ala¹⁶² mutant indicates no apparent differences between mutant and wild type hPR-B as shown in Fig. 11. Whole cell hormone binding assay also indicated no significant difference in affinity of the wild type and mutant receptors for R5020 (K_d = 0.16 nM for wild type hPR-B and 0.157 nM for Ala¹⁶² mutant (Fig. 12).

Analysis of antagonist/agonist switch.

All three of the B-specific mutants were transfected into CV-1 cells and analyzed for their ability to respond to RU 486 as an agonist in the presence of 8-Br-cAMP. In addition, a double mutant (Ala^{102,162}) and a triple mutant (Ala^{81,102,162}) were also tested. As shown in Fig. 13, all of the

hPR-B mutants examined appear to retain the low amount of "switch" activity observed in the presence of RU 486 and 8-Br-cAMP.

Analysis of Schule series of promoters.

As mentioned earlier, since the activity of any given phosphorylation site mutant PR might depend on with what co-transcription factors it interacts, I obtained a series of promoters from Schule (32) which all contain a single GRE in addition to another transcription factor binding site. A given phosphorylation site mutant PR may bind to a particular promoter and induce CAT activity differentially depending on whether phosphorylation of that site is necessary for activation in that particular promoter context. I initially attempted to characterize these promoters using our highly efficient adenovirus-mediated DNA transfer method for transfection. Perhaps because of its efficiency however, I was able to obtain only a low signal to noise ratio as the background was consistently so high. Hence, I have now moved to the less effective lipofectamine method of transfection which allows me to obtain a better signal to noise ratio at low receptor levels. Fig. 14 shows preliminary evidence with these reporters under conditions that I believe will be useful for determining any differences between the wild type and phosphorylation site mutant PR.

Conclusions:

Analysis of the Ala⁸¹ phosphorylation site mutant has revealed that obliterating phosphorylation of serine 81 results in a decrease in transactivation of a target reporter gene by this receptor.

Whether this observed decrease is intrinsic to the mutant receptor and is due to reduced activity per molecule of the receptor, or whether the absence of phosphorylation compromises the stability of the receptor leading to a consequent decrease in activation of the reporter gene remains to be clarified. Since this is an important question I am undertaking studies to determine the mechanism by which phosphorylation of Ser⁸¹ affects receptor function. Scatchard analysis indicates that it is not due to a decrease in affinity of the mutant PR for R5020. The preliminary Western analysis and hormone binding assay data, however, suggest a decrease in the amount of mutant PR protein compared to wild type. I will therefore examine protein stability of the two receptors using cycloheximide to block protein synthesis and measuring the turnover of receptor proteins from 0-72h using Western analysis.

Preliminary analysis of the other two B-specific phosphorylation sites, Ser¹⁰² and Ser¹⁶², shows no dramatic phenotypes under the conditions tested thus far using a simple promoter. However, now that I have established conditions for examining the Schule series of reporters which contain a single PRE binding site in addition to a binding site for another transcription factor, I will be able to examine the potential importance of phosphorylation in PR-mediated transcription from complex promoters. Interestingly, mutating Ser¹⁰² to alanine results in the disappearance of the upper migrating band generally detected on wild type hPR-B by Western analysis. This suggests that phosphorylation of Ser¹⁰² may change the conformation of the receptor such that it migrates slower through the gel and absence of this phosphorylation results in the receptor no longer migrating as a triplet of protein species.

The studies undertaken thus far have been under conditions where charcoal stripped serum has been used in the medium. This is generally accepted as a way of reducing non-specific background activation resulting from contaminating steroids in full serum. Unfortunately, heat inactivation and stripping of the serum also eliminate important growth factors that are necessary for regular cell growth and cell signaling. This becomes an issue when studying phosphorylation which requires many intricate signaling pathways to be operating in the cell. It will clearly be useful to examine the activities of the phosphorylation site mutant PR constructs under conditions which may give a truer indication of what is actually occurring. For example, we know that casein kinase II and cdk2 phosphorylate Ser⁸¹ and Ser¹⁶², respectively, of the hPR-B-specific sites. By over-expressing these kinases in cells we may be able to see an enhancement of wild type hPR-B mediated hormone-dependent activity not detectable with a particular phosphorylation site mutant PR, indicating a role for that phosphorylation site which would otherwise not be observable under the conditions currently being used.

All the B-specific phosphorylation site mutants appear not to be compromised in their ability to confer agonist activity on RU 486 in the presence of 8-Br-cAMP on a simple promoter.

Recently, a phospho-specific antibody which recognizes phosphorylated Ser²⁹⁴ on PR has been developed by our collaborator, Dean Edwards. Interestingly, this antibody appears to recognize hPR-B much more strongly than hPR-A in T47D breast cancer cells. This suggests that in vivo, this site is almost exclusively phosphorylated on the B-form of the receptor, making this another target for exploration with regards to the antagonist/agonist switch since the "switch" activity is specific to the hPR-B form of the receptor.

The work carried out to date on this project correlates very well with the statement of work in my original proposal.

Comparison of hPR-B and Ala⁸¹ PR activity in CV-1 cells




Figure 1: Comparison of hPR-B wild type and Ala⁸¹ PR using a GRE₂E1bCAT reporter in CV-1 cells. Cells were treated with 10⁻⁸M R5020.

Comparison of hPR-B and Ala⁸¹ PR activity in HeLa cells




Figure 2: Comparison of hPR-B and Ala⁸¹ PR using a GRE₂E1bCAT reporter in HeLa cells. Cells were treated with 10⁻⁸M R5020.

Comparison of wild type, Ala⁸¹ and Glu⁸¹ PR




Figure 3: Comparison of hPR-B wild type, Ala⁸¹ and Glu⁸¹mutant PR with GRE₂E1bCAT reporter in COS cells. Cells were treated with 10⁻⁸M R5020.




Figure 4: Scatchard analysis of hPR-B wild type and Ala⁸¹ mutant PR. Cells were transfected with either hPR-B wild type, Ala⁸¹ or empty pLEM vector and whole cell binding assays were carried out as described in Methods.

Western analysis of wild type and mutant PR




Figure 5. Wild type and mutant hPR-B (3ng) were transfected into HeLa cells. Mock transfected cells received pLEM empty vector. 30ug cell extract was separated by SDS-PAGE and probed with the #1294 antibody.




Figure 6: Comparison of hPR-B and Ala⁸¹ PR with MMTV-CAT reporter in A) HeLa cells and B) CV-1 cells. Cells were treated with 10⁻⁸M R5020




Figure 7: Comparison of 0.5 ng hPR-B wild type and Ala¹⁰² PR with GRE₂E1bCAT reporter in CV-1 cells.




Figure 8: Western analysis of hPR-B wild type and Ala¹⁰² PR in CV-1 cells

Scatchard analysis of wt and A¹⁰² PR




Figure 9: Scatchard analysis of wild type hPR-B and the Ala¹⁰² mutant. Whole cell binding assays were carried out as described in Methods.




Figure 10: Comparison of 0.5ng hPR-B wild type and Ala¹⁶² mutant PR with GRE₂E1bCAT reporter in CV-1 cells.




Figure 11: Western analysis of hPR-B wild type and Ala¹⁶² PR in CV-1 cells

Scatchard analysis of wt and A¹⁶²PR




Figure12: Scatchard analysis of wild type and A¹⁶² mutant PR.
Whole cell binding assays were carried out as described in Methods.

hPR-B specific phosphorylation site mutants exhibit antagonist/agonist switch




Figure 13: CV-1 cells were transfected with GRE₂E1bCAT reporter and PR. Treatments were as follows: 10⁻⁸M R5020 (H), 10⁻⁸M RU486 (RU), 1mM 8-Bromo-cAMP (8Br) or no treatment (-).




Figure 14: Comparison of CAT activity induced with three reporters (0.4 ug) from the Schule series with hPR-B (2.5ng) in HeLa cells. Background obtained with receptor, reporter and no hormone was subtracted from the hormone treated samples.

References

1. Russo, I.H. and Russo, J.H. Development of the human mammary gland. In: M.C. Neville and C.W. Daniel (eds.), *The Mammary Gland*, pp. 67 New York: Plenum. 1987.
2. Russo, I.H., Medado, J., and Russo, J. Endocrine influences on the mammary glands. In: T.C. Jones, U. Mohr and R.D. Hunt (eds.), *Integument and Mammary Glands*, pp. 252-266, Berlin: Springer. 1989.
3. Haslam, S.Z. Progesterone effects on deoxyribonucleic acid synthesis in normal mouse mammary glands. *Endocrinol.*, 122: 464-470, 1988.
4. Early Breast Cancer Trialist Collaborative Group Effects of adjuvant tamoxifen and of cytotoxic therapy or mortality in early breast cancer. *N. Engl. J. Med.*, 319: 1681-1692, 1988.
5. Horwitz, K.B. Antiprogestins and the treatment of breast cancer. In: M.S. Donaldson, L. Dorflinger, S.S. Brown and L.Z. Benet (eds.), *Clinical Applications of Mifepristone (RU486) and Other Antiprogestins*, pp. 210-229, Washington, D.C.: National Academy Press. 1993.
6. Evans, R.M. The steroid and thyroid hormone receptor superfamily. *Science*, 240: 889-895, 1988.
7. Carson-Jurica, M.A., Schrader, W.T., and O'Malley, B.W. Steroid receptor family: structure and functions. *Endocrine Revs.*, 11: 201-220, 1990.
8. Conneely, O.M., Maxwell, B.L., Toft, D.O., Schrader, W.T., and O'Malley, B.W. The A and B forms of the chicken progesterone receptor arise by alternate initiation of translation of a unique mRNA. *Biochem. Biophys. Res. Commun.*, 149: 493-501, 1987.
9. Jeltsch, J.M., Turcotte, B., Garnier, J.M., Lerouge, T., Krozowski, Z., Gronemeyer, H., and Chambon, P. Characterization of multiple mRNAs originating from the chicken progesterone receptor gene. *J. Biol. Chem.*, 265: 3967-3974, 1990.
10. Vegeto, E., Shahbaz, M.M., Wen, D.X., Goldman, M.E., O'Malley, B.W., and McDonnell, D.P. Human progesterone receptor A form is a cell and promoter specific repressor of human progesterone receptor B function. *Mol. Endocrinol.*, 7: 1244-1255, 1993.
11. McDonnell, D.P. and Goldman, M.E. RU486 exerts antiestrogenic activities through a novel progesterone receptor A form- mediated mechanism. *J. Biol. Chem.*, 269: 11945-11949, 1994.
12. Nichols, M., Weih, F., Schmid, W., DeVack, C., Kowenz-Leutz, E., Luckow, B., Boshart, M., and Schutz, G. Phosphorylation of CREB affects its binding to high and low affinity sites: implications for cAMP induced gene transcription. *EMBO J.*, 11: 3337-3346, 1992.

13. Boyle, W.J., Smeal, T., Defize, L.H.K., Angel, P., Woodgett, J.R., Karin, M., and Hunter, T. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. *Cell*, 64: 573-584, 1991.
14. Thanos, D. and Maniatis, T. NF-kB: A lesson in family values. *Cell*, 80: 529-532, 1995.
15. Auwerx, J. and Sassone-Corsi, P. IP-1: A dominant inhibitor of Fos/Jun whose activity is modulated by phosphorylation. *Cell*, 64: 983-993, 1991.
16. Chrivia, J.C., Kwok, R.P.S., Lamb, N., Hagiwara, M., Montminy, M.R., and Goodman, R.H. Phosphorylated CREB binds specifically to the nuclear protein CBP. *Nature*, 365: 855-859, 1993.
17. Denner, L.A., Schrader, W.T., O'Malley, B.W., and Weigel, N.L. Hormonal regulation and identification of chicken progesterone receptor phosphorylation sites. *J. Biol. Chem.*, 265: 16548-16555, 1990.
18. Bodwell, J.E., Orti, E., Coull, J.M., Pappin, D.J., Swift, F., and Smith, L.I. Identification of the phosphorylation sites in the mouse glucocorticoid receptor. *J. Biol. Chem.*, 266: 7549-7555, 1991.
19. Washburn, T.F., Hocutt, A., Brautigan, D.L., and Korach, K.S. Uterine estrogen receptor *in vivo*: phosphorylation of nuclear specific forms on serine residues. *Mol. Endocrinol.*, 5: 235-242, 1991.
20. Migliaccio, A., DiDomenico, M., Green, S., deFalco, A., Kajtaniak, E.L., Blasi, F., Chambon, P., and Auricchio, F. Phosphorylation on tyrosine of *in vitro* synthesized human estrogen receptor activates its hormone binding. *Mol. Endocrinol.*, 3: 1061-1069, 1989.
21. Arnold, S.F., Obourn, J.D., Jaffe, H., and Notides, A.C. Phosphorylation of the human estrogen receptor on tyrosine 537 *in vivo* and by Src family tyrosine kinases *in vitro*. *Mol. Endocrinol.*, 9: 24-33, 1995.
22. Rochette-Egly, C., Gaub, M.-P., Lutz, Y., Ali, S., Scheuer, I., and Chambon, P. Retinoic acid receptor-beta: Immunodetection and phosphorylation on tyrosine residues. *Mol. Endocrinol.*, 6: 2197-2209, 1992.
23. Poletti, A. and Weigel, N.L. Identification of a hormone-dependent phosphorylation site adjacent to the DNA-binding domain of the chicken progesterone receptor. *Mol. Endocrinol.*, 7: 241-246, 1993.
24. Beck, C.A., Weigel, N.L., and Edwards, D.P. Effects of hormone and cellular modulators of protein phosphorylation on transcriptional activity, DNA binding, and phosphorylation of human progesterone receptors. *Mol. Endocrinol.*, 6: 607-620, 1992.
25. Murphy, L.J., Murphy, L.C., and Friesen, H.G. Estrogen induces insulin-like growth factor-1 expression in the rat uterus. *Mol. Endocrinol.*, 1: 445-450, 1987.

26. Zhang, Y., Beck, C.A., Poletti, A., Edwards, D.P., and Weigel, N.L. Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. *Mol. Endocrinol.*, 9: 1029-1040, 1995.
27. Lydon, J.P., DeMayo, F.J., Funk, C.R., Mani, S.K., Hughes, A.R., Montgomery, Jr.C.A., Shyamala, G., Conneely, O.M., and O'Malley, B.W. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. *Genes and Dev.*, 9: 2266-2278, 1995.
28. Michna, H., Nishino, Y., Schneider, M.R., Lournon, T., and El Etreby, M.F. A bioassay for the evaluation of anti-proliferative potencies of progesterone antagonist. *J. Steroid Biochem. Mol. Biol.*, 38: 359-365, 1991.
29. Denner, L.A., Weigel, N.L., Maxwell, B.L., Schrader, W.T., and O'Malley, B.W. Regulation of progesterone receptor-mediated transcription by phosphorylation. *Science*, 250: 1740-1743, 1990.
30. Beck, C.A., Weigel, N.L., Moyer, M.L., Nordeen, S.K., and Edwards, D.P. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. *Proc. Natl. Acad. Sci. USA*, 90: 4441-4445, 1993.
31. Allgood, V.E., Zhang, Y., O'Malley, B.W., and Weigel, N.L. Analysis of chicken progesterone receptor function and phosphorylation using an adenovirus-mediated procedure for high efficiency DNA transfer. *Biochem.*, 36: 224-232, 1997.
32. Schule, R., Muller, M., Kaltschmidt, C., and Renkawitz, R. Many transcription factors interact synergistically with steroid receptors. *Science*, 242: 1418-1420, 1988.